Physician profile
Juergen Mueller
NPI 1376636043
$3,718.52
in general payments reported to CMS, 2019-2025
25 companies · $749 in 2025
The $749 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $429 · 2021: $249 · 2022: $762 · 2023: $558 · 2024: $752 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.95 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $461.08 | 2021-2025 | Entyvio |
| Pfizer INC. | $371.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.16 | 2019-2022 | |
| Janssen Biotech, INC. | $295.66 | 2021-2025 | Tremfya, Stelara |
| Celgene Corporation | $254.38 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $195.42 | 2019-2024 | |
| Braintree Laboratories, INC. | $160.35 | 2020-2025 | Suflave, Sutab |
| Gilead Sciences, INC. | $93.01 | 2019-2025 | |
| Genzyme Corporation | $73.05 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $72.66 | 2022-2025 | Oxlumo |
| Ardelyx, INC. | $66.49 | 2023-2024 | Ibsrela |
| Lilly USA, LLC | $46.91 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $42.94 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $38.25 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $35.35 | 2025 | Rezdiffra |
| Medtronic, INC. | $27.77 | 2021 | |
| Redhill Biopharma INC. | $24.80 | 2021 | |
| Novo Nordisk INC | $24.63 | 2025 | Wegovy |
| Sunovion Pharmaceuticals INC. | $20.47 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.09 | 2024 | Voquezna |
| Echosens North America, INC. | $17.30 | 2025 | Fibroscan |
| Daiichi Sankyo INC. | $16.23 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.33 | 2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $14.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juergen Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.